CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the...
Hence then, the article about clinical research results for kelun biotech s trop2 adc sacituzumab tirumotecan sac tmt published in nature medicine a top international medical journal was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal )
Also on site :
- Amazon's ‘Supportive’ Skechers Wedge Sandals Are ‘Great for Traveling’ and Just $31 Before the Big Spring Sale
- Beloved Singer-Songwriter Behind the Defining Rock Anthem of the 2000s Turns 51
- On This Date in 1979, an Iconic '70s Band Released Their Last Top 10 Hit